Sailong Pharmaceutical Group Co.,ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Sailong Pharmaceutical Group Co., Ltd. (referred to as "Sailong Pharmaceutical") was established in 2002 and is a high-tech enterprise that integrates drug research and development, production, and sales. Currently, its products are mainly concentrated in the fields of nervous system, cardiovascular and cerebrovascular system, and digestive system. After fifteen years of hard work, the company established its corporate philosophy of "leading with technology and achieving health" at the beginning of its establishment. It focuses on drug research and development that is in line with international standards, and has successfully developed cardiovascular and cerebrovascular drugs such as monosialotetrahexosylganglioside sodium and injection, as well as brain protein hydrolysates for injection. For many years, the company has taken providing "safe and efficient" drugs to society as its responsibility, closely grasping the pulse of industry development, and emphasizing technological innovation and new drug research and development. The research and development center has a first-class hardware facility in the Theron Building, equipped with a batch of large precision instruments recommended by the US FDA and recognized by international drug research and development institutions. It has gathered a group of knowledgeable, hardworking, and thoughtful scientific and technological personnel led by doctoral scholars and master's degrees, gradually building research platforms such as "chiral drugs", "slow-release drugs", and "biochemical drugs". We have successively obtained 11 drug approvals, multiple drug invention patents, and two clinical approvals, as well as more than ten supplementary research approvals, including "monosialotetrahexosylganglioside sodium". We have established our characteristics and advantages in drug research and development fields such as cardiovascular and cerebrovascular diseases, nervous system, new antibiotics, and digestive system. Sailong Pharmaceutical is well aware that drugs are a special commodity for treating diseases and saving people. The excellent quality of each drug is the eternal pursuit of the company. Real time monitoring of the cleanliness of the production environment throughout the entire process and multi-point endotoxin monitoring of intermediate products throughout the process all reflect the spirit of striving for excellence as a great craftsman. At present, the company has built a modern production line with advanced facilities for freeze-dried powder injections, small capacity injections, biochemical raw materials, and chemical synthetic raw materials. It has a complete set of modern production and inspection equipment, and has repeatedly passed GMP certification for all production lines with high standards. It has been recognized as a high-tech enterprise and its products are best-selling in 30 provinces, cities, and autonomous regions. Looking forward to the future, the company will continue to uphold the purpose of "leading with technology and achieving health cause", practice the corporate culture of "unity, hard work, dedication, and dedication", and dedicate outstanding scientific research achievements and efficient and high-quality health products to the cause of human health. |
| Headquarter | Zhuhai |
| Establish Date | 4/3/2002 |
| Listed Code | 002898.SZ |
| Listed Date | 9/12/2017 |
| Chairman | Cai Nangui. |
| CEO | Cai Chinong. |
| Website | www.sailong.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
